Everything researchers need on Thymosin Alpha-1. Full immune mechanism, the complete clinical trial database across hepatitis, cancer, sepsis, and COVID-19, the Zadaxin dosing protocol, reconstitution, stacking considerations, and current vendor pricing.
Thymosin Alpha-1 is a 28-amino acid peptide with the sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. Molecular weight: 3,108 Da.
Key structural features: N-terminal acetylation (the Ac- prefix) protects against aminopeptidase degradation and is essential for biological activity — non-acetylated forms show significantly reduced potency. The predominantly acidic character of the peptide (high glutamate/aspartate content) contributes to its interaction with immune cell surface receptors. Synthetic Tα1 is identical in structure and activity to the naturally occurring thymic peptide.
Tα1 activates toll-like receptor (TLR) signaling pathways in dendritic cells and macrophages, triggering innate immune responses that are the first line of defense against pathogens. Specifically, it signals through TLR2 and TLR9, inducing production of type I interferons and pro-inflammatory cytokines that alert the adaptive immune system. This is the mechanism by which Tα1 accelerates early antiviral responses — it essentially tells the innate system to sound the alarm more effectively.
The adaptive immune effects of Tα1 are the most characterized and clinically relevant:
Natural killer cells provide immune surveillance without requiring prior antigen exposure. Tα1 enhances NK cell cytotoxicity and proliferation, improving the innate immune system's ability to clear virally infected cells and early tumor cells before the adaptive response has fully mobilized.
Dendritic cells are the bridge between innate and adaptive immunity — they capture antigens and present them to T-cells to initiate specific immune responses. Tα1 promotes dendritic cell maturation and enhances their antigen-presenting capability, effectively improving the quality of the immune system's ability to mount targeted responses against specific threats.
The most established indication. Multiple RCTs across Asia and Europe showed Tα1 significantly improves HBeAg seroconversion (marker of chronic HBV suppression) and ALT normalization compared to placebo. A meta-analysis of 11 trials confirmed the benefit. The mechanism is enhancement of HBV-specific T-cell responses that chronic HBV suppresses.
Multiple trials showed benefit as monotherapy and in combination with interferon-alpha. The combination appears synergistic — Tα1 enhances the T-cell response while interferon provides direct antiviral activity. Particularly relevant in patients who fail or don't tolerate standard treatment.
Tα1 has been studied in lung cancer, hepatocellular carcinoma, melanoma, and others. The primary finding across multiple trials: improved immune parameters (T-cell counts, NK activity) during chemotherapy, and in several studies, improved clinical outcomes. The rationale is that chemotherapy causes significant immunosuppression; Tα1 partially counteracts this, allowing better residual immune surveillance.
Chinese Phase 3 trials in sepsis showed reduced 28-day mortality in patients treated with Tα1 versus standard care. The mechanism targets sepsis-induced immunosuppression — the "immunoparalysis" phase where the immune system fails to clear the original infection after the initial inflammatory storm. Tα1 restores T-cell function in this compromised state.
Multiple trials during 2020–2022 showed Tα1 reduced progression to severe disease and mortality in hospitalized COVID-19 patients. Proposed mechanism: restoration of depleted T-cell counts (severe COVID causes profound lymphopenia) and enhancement of antiviral T-cell responses. Results were consistent across multiple Chinese centers and contributed to its emergency use in several countries.
Pre-ART era trials showed benefit in improving CD4 counts and reducing opportunistic infections. Less relevant in the current ART era but historically important in establishing the immune restoration profile.
| Application | Dose | Frequency | Duration |
|---|---|---|---|
| Standard immune support | 0.5–1.6mg | 2–3x weekly | 6–12 weeks |
| Zadaxin (clinical) protocol | 1.6mg | Twice weekly | 6 months (hepatitis) |
| Acute infection | 1.6mg | Daily for 1 week, then 3x/week | 4–8 weeks |
| Longevity / immunosenescence | 0.5–1.6mg | 2x weekly | Ongoing (periodic cycling) |
| Cancer adjunct | 1.6mg | 3x weekly | Duration of treatment + 4 weeks post |
Tα1 is commonly stacked in longevity and immune restoration protocols. Common combinations:
No known adverse interactions between Tα1 and other peptides. Given its clean safety profile, it stacks freely with most research peptide protocols.
Thymosin Alpha-1 has one of the most favorable safety profiles in the peptide research space, based on decades of clinical use and thousands of trial participants:
Current pricing from vetted vendors — check the main page for live updates.